These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24487366)

  • 1. Lipoprotein glomerulopathy may provide a key to unlock the puzzles of renal lipidosis.
    Saito T; Matsunaga A
    Kidney Int; 2014 Feb; 85(2):243-5. PubMed ID: 24487366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation.
    Hu Z; Huang S; Wu Y; Liu Y; Liu X; Su D; Tao Y; Fu P; Zhang X; Peng Z; Zhang S; Yang Y
    Kidney Int; 2014 Feb; 85(2):416-24. PubMed ID: 24025644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topics in lipoprotein glomerulopathy: an overview.
    Saito T; Matsunaga A; Ito K; Nakashima H
    Clin Exp Nephrol; 2014 Apr; 18(2):214-7. PubMed ID: 24149835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New evolution in lipoprotein glomerulopathy].
    Saito T; Matsunaga A; Nakashima H
    Nihon Jinzo Gakkai Shi; 2013; 55(7):1314-9. PubMed ID: 24288968
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipoprotein glomerulopathy with markedly increased arterial stiffness successfully treated with a combination of fenofibrate and losartan: a case report.
    Kato J; Okonogi H; Kanzaki G; Katsumata H; Nakada Y; Sagasaki M; Komine K; Ito K; Saito T; Matsunaga A; Tokutou K; Honda K; Tsuboi N; Yokoo T
    BMC Nephrol; 2024 May; 25(1):171. PubMed ID: 38769490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy.
    Arai T; Yamashita S; Yamane M; Manabe N; Matsuzaki T; Kiriyama K; Kanayama Y; Himeno S; Matsuzawa Y
    Atherosclerosis; 2003 Aug; 169(2):293-9. PubMed ID: 12921981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy.
    Ieiri N; Hotta O; Taguma Y
    Am J Kidney Dis; 2003 Jan; 41(1):244-9. PubMed ID: 12500244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of a novel apolipoprotein E variant, ApoE Osaka/Kurashiki, in lipoprotein glomerulopathy.
    Saito T; Matsunaga A
    J Atheroscler Thromb; 2011; 18(6):542-3. PubMed ID: 21670560
    [No Abstract]   [Full Text] [Related]  

  • 9. Lipoprotein glomerulopathy in China.
    Chen Y
    Clin Exp Nephrol; 2014 Apr; 18(2):218-9. PubMed ID: 24165683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy.
    Tokura T; Itano S; Kobayashi S; Kuwabara A; Fujimoto S; Horike H; Satoh M; Komai N; Tomita N; Matsunaga A; Saito T; Sasaki T; Kashihara N
    J Atheroscler Thromb; 2011; 18(6):536-41. PubMed ID: 21467726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein E-related glomerular disorders.
    Saito T; Matsunaga A; Fukunaga M; Nagahama K; Hara S; Muso E
    Kidney Int; 2020 Feb; 97(2):279-288. PubMed ID: 31874799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy.
    Bomback AS; Song H; D'Agati VD; Cohen SD; Neal A; Appel GB; Rovin BH
    Nephrol Dial Transplant; 2010 Oct; 25(10):3442-6. PubMed ID: 20624773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis, histopathologic findings and treatment modalities of lipoprotein glomerulopathy: A review.
    Cambruzzi E; Pêgas KL
    J Bras Nefrol; 2019; 41(3):393-399. PubMed ID: 30421781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein e mutation and double filtration plasmapheresis therapy on a new Chinese patient with lipoprotein glomerulopathy.
    Li W; Wang Y; Han Z; Luo C; Zhang C; Xiong J
    Kidney Blood Press Res; 2014; 39(4):330-9. PubMed ID: 25300642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.
    Matsunaga A; Sasaki J; Komatsu T; Kanatsu K; Tsuji E; Moriyama K; Koga T; Arakawa K; Oikawa S; Saito T; Kita T; Doi T
    Kidney Int; 1999 Aug; 56(2):421-7. PubMed ID: 10432380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Novel Apolipoprotein E Mutation ApoE Chengdu (c.518T＞C, p.L173P) in a Chinese Patient with Lipoprotein Glomerulopathy.
    Wu H; Yang Y; Hu Z
    J Atheroscler Thromb; 2018 Aug; 25(8):733-740. PubMed ID: 29398675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports.
    Wang R; Zhao C; Chen W; Liu Z; Xie F
    J Med Case Rep; 2022 Feb; 16(1):78. PubMed ID: 35193676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy.
    Toyota K; Hashimoto T; Ogino D; Matsunaga A; Ito M; Masakane I; Degawa N; Sato H; Shirai S; Umetsu K; Tamiya G; Saito T; Hayasaka K
    J Hum Genet; 2013 May; 58(5):254-8. PubMed ID: 23407349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy.
    Rovin BH; Roncone D; McKinley A; Nadasdy T; Korbet SM; Schwartz MM
    N Engl J Med; 2007 Dec; 357(24):2522-4. PubMed ID: 18077821
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases.
    Saito T; Matsunaga A; Oikawa S
    Am J Kidney Dis; 2006 Feb; 47(2):199-211. PubMed ID: 16431249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.